News | October 24, 2018

PRINCIPIA BIOPHARMA APPOINTS DOLCA THOMAS, M.D. AS CHIEF MEDICAL OFFICER – Succession designed to lead Principia through next phase of growth as a clinical-stage company – SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) — Principia...

News | October 19, 2018

PRINCIPIA BIOPHARMA ANNOUNCES PRN1008 RECEIVES ORPHAN-DRUG DESIGNATION FROM FDA FOR TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA SOUTH SAN FRANCISCO, Calif., Oct. 19, 2018 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage...

News | October 16, 2018

PRINCIPIA ACHIEVES $10 MILLION IN ADDITIONAL MILESTONES RELATED TO DEVELOPMENT OF PRN2246/SAR442168 — Additional milestones achieved under the Sanofi collaboration which is focused on treating diseases of the central nervous system — SOUTH SAN FRANCISCO,...

News | October 17, 2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases Kathleen Sereda Glaub Appointed Executive Chair and Anthony Ford, PhD, Named Chief...

News | October 3, 2018

HARPOON THERAPEUTICS ANNOUNCES APPOINTMENT OF NATALIE R. SACKS, M.D., AS CHIEF MEDICAL OFFICER South San Francisco, CA – October 3, 2018 – Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a new class of T cell engaging therapeutics,...
tempus ut risus elit. sit ut